S&P 500 falls after giving up gains as Oracle slump weighs on tech
Propanc Biopharma Inc. (PPCB) reported fiscal year-end results and announced plans to establish a digital asset treasury valued at $100 million or more over the next 12 months, according to a company statement.
The biopharmaceutical company, which develops cancer treatments, completed its initial public offering and began trading on Nasdaq on August 14, 2025. For the fiscal year ending June 30, 2025, total assets increased to $19.6 million from approximately $72,000 in the prior year.
Stockholders’ equity rose to $13.9 million from a deficit of $3.8 million. The company attributed the asset growth primarily to prepaid service contracts related to market awareness, advisory, accounting, finance, manufacturing, and research and development activities.
Following the Nasdaq listing, Propanc entered an underwriting agreement with D Boral Capital and completed an offering of 1 million common shares, generating gross proceeds of $4 million.
"The Company is focused on advancing our lead therapeutic candidate and further building our intellectual property portfolio with various development milestones anticipated by the end of 2025 and throughout 2026," said CEO James Nathanielsz in the statement.
Regarding the digital asset strategy, Nathanielsz noted that over 200 public companies currently hold digital assets in their treasuries, primarily Bitcoin but increasingly Ethereum, Solana, and other cryptocurrencies.
Propanc develops treatments for recurring and metastatic cancer, focusing on pancreatic proenzymes that target cancer stem cells in patients with pancreatic, ovarian, and colorectal cancers. The company filed its annual 10-K report with the Securities and Exchange Commission on September 29, 2025.